drugset / Trial / NCT06228482
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6
Phase 1
Recruiting
40 enrolled
University of California, Davis
United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).
Timeline
- Start
- 2024-01-22
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [177Lu]Lu DOTA-ABM-5G | Unknown | — | — |
| Subject | [68Ga]Ga DOTA-5G | Diagnostic / imaging agent | — | — |